eligibility_summary
Adults (≥18) with ECOG 0–1 after complete resection (R0/R1) of pancreatic cancer without metastasis, no prior anti-tumor therapy, adequate marrow/organ function, LVEF ≥50%, agree to contraception, able to consent/comply. Exclude: other trials within 4 weeks, other malignancy, immunodeficiency, significant postop complications, pregnancy/lactation, substance abuse/psychosocial barriers, allergy to nimotuzumab or study chemo agents.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Single-arm phase 2 adjuvant trial testing: 1) Nimotuzumab—humanized IgG1 monoclonal antibody (biologic) targeting EGFR, blocks ligand binding and downstream EGFR signaling (RAS/RAF/MEK/ERK, PI3K/AKT) and may trigger ADCC. 2) mFOLFIRINOX chemotherapy: oxaliplatin (DNA crosslinking platinum), irinotecan (topoisomerase I inhibitor), 5‑fluorouracil (antimetabolite, thymidylate synthase inhibitor, RNA/DNA incorporation), with leucovorin to potentiate 5‑FU. 3) GX chemotherapy: gemcitabine (nucleoside analog, ribonucleotide reductase inhibition and DNA chain termination) + capecitabine (oral 5‑FU prodrug). Targets: EGFR-expressing pancreatic tumor cells, DNA replication/repair, thymidylate synthase, topoisomerase I, ribonucleotide reductase, induces cytotoxicity in rapidly dividing cells.